Atrium Therapeutics, Inc. Common Stock (RNA) Stock Forecast & Price Target
Atrium Therapeutics, Inc. Common Stock · NASDAQ
$11.50-0.07 (-0.61%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 15 firms covering Atrium Therapeutics, Inc. Common Stock, 7 rate it Buy or better, 8 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $25.00 to $74.00 (about 3.0x), a sign of real disagreement on valuation. The average target of $59.14 sits 414% above the current $11.50. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.70 next quarter toward $-5.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 ratings
Moderate Buy
Strong Buy00%
Buy747%
Hold853%
Sell00%
Strong Sell00%
Based on 15 analysts giving stock ratings to Atrium Therapeutics, Inc. Common Stock.
As of Jul, 7 of 15 firms rate RNA a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RNA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.70
Range $-0.70 – $-0.70 · 1 analysts
Next period, 1 analysts expect Atrium Therapeutics, Inc. Common Stock to earn $-0.70 a share (range $-0.70 – $-0.70), versus — a year earlier. Full-year consensus is $-3.59, growing to $-5.85 the year after.
REVENUE · NEXT QUARTER
$666.7K
Range $0 – $2.0M · 1 analysts
Revenue is expected to reach $666.7K (range $0 – $2.0M). Full-year consensus is $21.6M, rising to $2.7M next year.
Top analysts covering Atrium Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RNA.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$68.00+491.3% to target
Overall win rate
46%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #130
Hold
$72.00+526.1% to target
Overall win rate
41%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$25.00+117.4% to target
Overall win rate
38%
+ Follow
#4
Joseph Stringer
Needham · Rank #168
Hold
$65.00+465.2% to target
Overall win rate
36%
+ Follow
#5
Yanan Zhu
Wells Fargo
Buy
$25.00+117.4% to target
Coverage
—
+ Follow
RNA stock forecast FAQ
What is RNA's average 12-month price target?+
The 14 analysts with a live target average $59.14 for Atrium Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $74.00 high to a $25.00 low.
Is RNA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 15 analyst ratings, 7 are Buy or Strong Buy, 8 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RNA?+
The Street-high target is $74.00 (TD Cowen), and the Street-low is $25.00 (Cantor Fitzgerald). The average of all 14 active targets is $59.14.
How many Wall Street analysts cover RNA?+
15 analysts have an active rating on Atrium Therapeutics, Inc. Common Stock, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering RNA?+
Among analysts who currently cover RNA, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $68.00 target.
What is Atrium Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.70 per share (range $-0.70 – $-0.70) across 1 analysts. Full-year EPS is projected at $-3.59, rising to $-5.85 the following year.
How much revenue is Atrium Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $666.7K (range $0 – $2.0M). Full-year revenue is projected at $21.6M, growing to $2.7M next year.
Have analysts been upgrading or downgrading RNA lately?+
As of Jul, 7 of 15 firms rate RNA a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
